Want to see TSE:MDP full AI Analyst Report?

Medexus Pharmaceuticals Inc (MDP) Price & Analysis

72 Followers

MDP Stock Chart & Stats

C$5.04

-C$0.06(-1.18%)

At close: Jul 24 4:00 PM EDT

C$5.04

-C$0.06(-1.18%)

Day’s Range― - ―

52-Week RangeC$2.51 - C$5.50

Previous CloseN/A

Volume6.46K

Average Volume (3M)46.68K

Market Cap

C$161.84M

Enterprise ValueC$192.00

Total Cash (Recent Filing)C$5.34M

Total Debt (Recent Filing)C$26.21M

Price to Earnings (P/E)―

Beta0.97

Next Earnings

Nov 11, 2026

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding31,425,983

10 Day Avg. Volume30,861

30 Day Avg. Volume46,683

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)2.06

Price to Sales (P/S)1.02

P/FCF Ratio27.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$6.50

Price Target Upside28.97% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)0.18

Revenue Forecast (FY)C$116.53M

Bulls Say, Bears Say

Bulls Say

GRAFAPEX AdoptionBroad institutional uptake and repeat ordering indicate durable product acceptance rather than one-time stocking. Continued patient-demand growth can support recurring revenue and strengthen Medexus’s position in specialty hospital care.

Revenue And EBITDA GrowthImproving revenue, EBITDA and operating income show operating leverage as commercialization scales. If sustained, this progress can improve the company’s earnings quality and provide greater capacity to fund product expansion.

Portfolio ExpansionAdding UM171 expands the hematology and cell-therapy portfolio and leverages Medexus’s existing allo-HSCT commercial expertise. A potential expedited Canadian regulatory path could create another durable growth opportunity beyond current products.

Bears Say

Persistent Net LossesDespite positive gross and operating margins, recurring net losses indicate that the business has not yet converted commercialization activity into durable bottom-line profitability. Negative ROE also shows the equity base remains underproductive.

Weak Cash ConversionNegative trailing free cash flow limits financial flexibility and makes growth more dependent on working-capital management or external funding. The deterioration from the prior year suggests current expansion is absorbing cash before benefits fully mature.

Product Concentration And CompetitionDependence on GRAFAPEX concentrates execution risk in one growth product, while generic competition for Rasuvo and possible tariffs could pressure revenue or margins. These factors may make the portfolio’s long-term performance less predictable.

Medexus Pharmaceuticals Inc News

Analyst Lifts Medexus Price Target to C$6.50 and Reiterates Buy on Strong Grafapex-Driven Performance

David Martin PhD, an analyst from Bloom Burton, maintained the Buy rating on Medexus Pharmaceuticals Inc. The associated...

7d ago

Medexus Q1 Profitability Surges on Record GRAFAPEX Performance

Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) has provided an announcement. Medexus reported a strong fiscal Q1 2027, driven...

10d ago

Medexus: Buy Rating Reiterated as Analyst Sees Leaner Cost Base, Growing U.S. Portfolio and Pipeline Upside Supporting C$6.00 Target Price

Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Medexus Pharmaceuticals Inc, with a price...

2M ago

Medexus Earnings Call: GRAFAPEX Offsets Transition Strain

Medexus Pharmaceuticals (($TSE:MDP)) has held its Q4 earnings call. Read on for the main highlights of the call....

2M ago

MDP Earnings this Week: How Will it Perform?

Medexus Pharmaceuticals (MDP) is scheduled to report 4th quarter earnings on 06/25/2026, after the market closes. Regarding Q4...

2M ago

Medexus Advances U.S. GRAFAPEX Rollout While Streamlining Capital Structure

An update from Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) is now available. Medexus Pharmaceuticals reported continued progress in...

4M ago

Medexus Pharmaceuticals: Channel Headwinds Masking Demand as Strategic Positioning Supports Buy-Rated Risk‑Reward

David Martin PhD, an analyst from Bloom Burton, maintained the Buy rating on Medexus Pharmaceuticals Inc. The associated...

6M ago

Medexus Pharmaceuticals Balances GRAFAPEX Growth With Headwinds

Medexus Pharmaceuticals (($TSE:MDP)) has held its Q3 earnings call. Read on for the main highlights of the call....

6M ago

Is MDP a Buy, Before Earnings?

Medexus Pharmaceuticals (MDP) is scheduled to report 3rd quarter earnings on 02/11/2026, after the market closes. Regarding Q3...

6M ago

Medexus Sets Date for Q3 2026 Earnings Call and Webcast

An update from Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) is now available. Medexus Pharmaceuticals has scheduled a conference...

7M ago

MDP FAQ

What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?

Medexus Pharmaceuticals Inc lowest stock price was C$2.51 and its highest was C$5.50 in the past 12 months.

What is Medexus Pharmaceuticals Inc’s market cap?

Medexus Pharmaceuticals Inc’s market cap is C$161.84M.

When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?

Medexus Pharmaceuticals Inc’s upcoming earnings report date is Nov 11, 2026 which is in 83 days.

How were Medexus Pharmaceuticals Inc’s earnings last quarter?

Medexus Pharmaceuticals Inc released its earnings results on Aug 10, 2026. The company reported C$0.028 earnings per share for the quarter, missing the consensus estimate of C$0.044 by -C$0.017.

Is Medexus Pharmaceuticals Inc overvalued?

According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medexus Pharmaceuticals Inc pay dividends?

Medexus Pharmaceuticals Inc does not currently pay dividends.

What is Medexus Pharmaceuticals Inc’s EPS estimate?

Medexus Pharmaceuticals Inc’s EPS estimate is 0.02.

How many shares outstanding does Medexus Pharmaceuticals Inc have?

Medexus Pharmaceuticals Inc has 31,425,983 shares outstanding.

What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?

Medexus Pharmaceuticals Inc reported an EPS of C$0.028 in its last earnings report, missing expectations of C$0.044. Following the earnings report the stock price went up 6.855%.

Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in TSE:MDP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Medexus Pharmaceuticals Inc Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
C$6.50 (28.97% Upside)

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-16.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.

Medexus Pharmaceuticals Inc (MDP) Earnings & Revenues

Historic Earnings Reports

MDP Stock 12 Month Forecast

Average Price Target

C$6.50

▲(28.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"C$1","4":"C$4","7":"C$7","2.5":"C$2.5","5.5":"C$5.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$6.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$6.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$6.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.5,4,5.5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.02,5.133846153846154,5.247692307692307,5.361538461538461,5.475384615384615,5.589230769230769,5.703076923076923,5.816923076923077,5.930769230769231,6.044615384615384,6.158461538461538,6.272307692307692,6.386153846153846,{"y":6.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.02,5.133846153846154,5.247692307692307,5.361538461538461,5.475384615384615,5.589230769230769,5.703076923076923,5.816923076923077,5.930769230769231,6.044615384615384,6.158461538461538,6.272307692307692,6.386153846153846,{"y":6.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.02,5.133846153846154,5.247692307692307,5.361538461538461,5.475384615384615,5.589230769230769,5.703076923076923,5.816923076923077,5.930769230769231,6.044615384615384,6.158461538461538,6.272307692307692,6.386153846153846,{"y":6.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.05,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.15,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.02,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >